%{search_type} search results

5,215 catalog results

RSS feed for this result
Book
ix, 136 pages ; 22 cm.
Green Library
Book
xv, 240 pages ; 24 cm
  • Proprietary medicines and the fiscal state
  • The medicine stamp duty and the authority of law
  • The tax and the profession of pharmacy
  • The tax and the integrity of medicines
  • The demise of the tax.
Law Library (Crown)
Book
xv, 240 pages : illustrations ; 24 cm
  • 1. Proprietary medicines and the fiscal state-- 2. The medicine stamp duty and the authority of law-- 3. The tax and the profession of pharmacy-- 4. The tax and the integrity of medicines-- 5. The demise of the tax.
  • (source: Nielsen Book Data)9781107025455 20171127
In 1783, a stamp duty was imposed on proprietary or 'quack' medicines. These largely useless but often dangerous remedies were immensely popular. The tax, which lasted until 1941, was imposed to raise revenue. It failed in its incidental regulatory purpose, had a negative effect in that the stamp was perceived as a guarantee of quality, and had a positive effect in encouraging disclosure of the formula. The book explains the considerable impact the tax had on chemists and druggists - how it led to an improvement in professional status, but undermined it by reinforcing their reputations as traders. The legislation imposing the tax was complex, ambiguous and never reformed. The tax authorities had to administer it, and executive practice came to dominate it. A minor, specialised, low-yield tax is shown to be of real significance in the pharmaceutical context, and of exceptional importance as a model revealing the wider impact of tax law and administration.
(source: Nielsen Book Data)9781107025455 20171127
SAL3 (off-campus storage)
Book
1 online resource : text file, PDF
  • Foreword Chapter 1: Inhaled proteins and peptides. Chapter 2: Inhaled insulin: More compelling than ever. Chapter 3: Inhaled therapeutic siRNA for the treatment of respiratory diseases. Chapter 4: New molecules to treat asthma and COPD. Chapter 5: Inhaled anti-cancer agents. Chapter 6: Inhaled countermeasures for respiratory tract viruses. Chapter 7: Pulmonary delivery of antibiotics for respiratory infections. Chapter 8: Inhaled liposomes. Chapter 9: Inhaled traditional Chinese medicine for respiratory diseases. Chapter 10: Bronchoprovocation tests for evaluation of drug efficacy in asthma.
  • (source: Nielsen Book Data)9781498758048 20171218
The respiratory tract has been used to deliver biologically active chemicals into the human body for centuries. However, the lungs are complex in their anatomy and physiology, which poses challenges to drug delivery. Inhaled formulations are generally more sophisticated than those for oral and parenteral administration. Pulmonary drug development is therefore a highly specialized area because of its many unique issues and challenges. Rapid progress is being made and offers novel solutions to existing treatment problems. Advances in Pulmonary Drug Delivery highlights the latest developments in this field.
(source: Nielsen Book Data)9781498758048 20171218
Book
1 online resource (x, 226 pages) : illustrations.
  • 1. Alcohol a double-edged sword: Health benefits with moderate consumption but a health hazard with excess alcohol intake 2. Drugs of abuse: An overview 3. Designer drugs including bath salts and spices 4. Combined alcohol and drug abuse: A potentially deadly mix 5. Link between environmental factors, personality factors, and addiction 6. Genetic polymorphisms of alcohol metabolizing enzymes associated with protection from or increased risk of alcohol abuse 7. Pharmacogenomics of abused drugs 8. Association between polymorphisms in genes encoding various receptors, transporters, and enzymes and alcohol/drug addiction 9. Methods of alcohol measurement 10. Laboratory methods for measuring drugs of abuse in urine 11. Analysis of drugs of abuse in serum, hair, oral fluid, sweat, and meconium.
  • (source: Nielsen Book Data)9780128054550 20170313
Alcohol, Drugs, Genes and the Clinical Laboratory provides an overview and quick reference to genetic relationships and clinical laboratory information related to the serious public health issue of alcohol and drug abuse. Written in a clear and concise manner, this book discusses the necessary information for health and safety professionals working in public health to learn about complex issues quickly to better help their patients, employees, and others affected by alcohol and drug abuse. Alcohol, Drugs, Genes and the Clinical Laboratory covers the important aspects of drugs and alcohol abuse including genetic aspects along with laboratory methods for analysis of alcohol and abused drugs with emphasis on false positive test results. The book is helpful to healthcare professionals, such as pathologists who oversee alcohol and drug testing, emergency room physicians, family practice physicians who are first healthcare professionals who identify patients susceptible to drug and alcohol abuse, and psychiatrists involved with drug and alcohol rehabilitation programs. It will also be useful to safety professionals who have to assess individuals for workplace responsibilities, ranging from police and recruitment to occupational safety and occupational medicine and public health officials.
(source: Nielsen Book Data)9780128054550 20170313
Book
1 online resource.
The definitive guide to the myriad analytical techniques available to scientists involved in biotherapeutics research Analytical Characterization of Biotherapeutics covers all current and emerging analytical tools and techniques used for the characterization of therapeutic proteins and antigen reagents. From basic recombinant antigen and antibody characterization, to complex analyses for increasingly complex molecular designs, the book explores the history of the analysis techniques and offers valuable insights into the most important emerging analytical solutions. In addition, it frames critical questions warranting attention in the design and delivery of a therapeutic protein, exposes analytical challenges that may occur when characterizing these molecules, and presents a number of tested solutions. The first single-volume guide of its kind, Analytical Characterization of Biotherapeutics brings together contributions from scientists at the leading edge of biotherapeutics research and manufacturing. Key topics covered in-depth include the structural characterization of recombinant proteins and antibodies, antibody de novo sequencing, characterization of antibody drug conjugates, characterization of bi-specific or other hybrid molecules, characterization of manufacturing host-cell contaminant proteins, analytical tools for biologics molecular assessment, and more. Each chapter is written by a recognized expert or experts in their field who discuss current and cutting edge approaches to fully characterizing biotherapeutic proteins and antigen reagentsCovers the full range of characterization strategies for large molecule based therapeuticsProvides an up-to-date account of the latest approaches used for large molecule characterizationChapters cover the background needed to understand the challenges at hand, solutions to characterize these large molecules, and a summary of emerging options for analytical characterization Analytical Characterization of Biotherapeutics is an up-to-date resource for analytical scientists, biologists, and mass spectrometrists involved in the analysis of biomolecules, as well as scientists employed in the pharmaceuticals and biotechnology industries. Graduate students in biology and analytical science, and their instructors will find it to be fascinating and instructive supplementary reading.
(source: Nielsen Book Data)9781119053101 20170731
Book
1 online resource (xxi, 570 pages) : illustrations.
  • Anti-Aging Drugs: Where are We and Where are We Going? / Alexander M. Vaiserman and Oleh V. Lushchak
  • Aging: Natural or Disease? A View from Medical Textbooks / S. Janac, B. Clarke and D. Gems
  • The Search for the "Anti-Aging Pill": A Critical Viewpoint / Éric le Bourg
  • Testing of Geroprotectors in Experiments on Cell Cultures: Pros and Cons / Alexander N. Khokhlov and Galina V. Morgunova
  • Pharmacogenomics and Epigenomics of Age-Related Neurodegenerative Disorders: Strategies for Drug Development / Ramón Cacabelos, Juan Carlos Carril and Oscar Teijido
  • Nanotechnology in Anti-Aging: Nutraceutical Delivery and Related Applications / Anila Mathew, Francesco Marotta and D. Sakthi Kumar
  • Hormetins as Drugs for Healthy Aging / Suresh I. S. Rattan
  • Antioxidant Therapy of Aging: From Free Radical Chemistry to Systems Theory of Reliability / V. K. Koltover
  • Mitochondria-Targeted Rechargeable Antioxidants as Potential Anti-Aging Drugs / Elena G. Pasyukova, Boris A. Feniouk and Vladimir P. Skulachev
  • Mimetics of Caloric Restriction / Oleh Lushchak and Dmytro Gospodaryov
  • Allosteric SIRT1 Activators as Putative Anti-Aging Drugs / Basil P. Hubbard
  • Therapeutic Potential of Sirtuin Inhibitors in Cancer / Francisco Javier Alcain, Consuelo M. Nieva, Lucía Fernández del Río, Raquel Santiago-Mora, Elena Gutiérrez-Casado, Mario Duran-Prado and Jose M. Villalba
  • Lifespan-Extending Effect of Resveratrol and Other Phytochemicals / Shin-Hae Lee and Kyung-Jin Min
  • Extending Lifespan by Inhibiting the Mechanistic Target of Rapamycin (mTOR) / Dudley W. Lamming
  • mTOR, Aging and Cancer: Prospects for Pharmacological Interventions / Z. D. Sharp
  • Anti-Aging Action of PPARs: Potential Therapeutic Targets / Ki Wung Chung, Byung Pal Yu and Hae Young Chung
  • Antidiabetic Biguanides as Anti-Aging Drugs / Vladimir N. Anisimov
  • S-Adenosylmethionine Metabolism: A Promising Avenue in Anti-Aging Medicine? / W. A. M. Loenen
  • Melatonin as a Geroprotector: Healthy Aging vs. Extension of Lifespan / R. Hardeland
  • Short Peptides Regulate Gene Expression, Protein Synthesis and Enhance Life Span / Vladimir Khavinson and Irina Popovich
  • HDAC Inhibitors: A New Avenue in Anti-Aging Medicine / E. G. Pasyukova and A. M. Vaiserman
  • Human Life Extension: Opportunities, Challenges, and Implications for Public Health Policy / Ilia Stambler.
Provides an overview of current research aimed to search for life-extending medications and describes pharmacological aspects of anti-aging medicine. Readers are introduced to the historical background of geroprotection in the first chapter. In-depth information on models for investigating geroprotective drugs precedes a section covering anti-aging properties of pharmaceutical compounds, such as calorie restriction mimetics, autophagy inducers, senolytics and mitochondrial antioxidants. Finally, strategies to translate discoveries from aging research into drugs and healthcare policy perspectives on anti-ageing medicine are provided to give a complete picture of the field.
Book
xxv, 434 pages : illustrations ; [ca. 23-29] cm.
  • Bioequivalence & Biopharmaceutical Development Drug Development and Clinical Pharmacology Aims of This Book Biopharmaceutical Development Clinical Pharmacology Statistics in Clinical Pharmacology Structure of the Book History and Regulation of Bioequivalence When and How BE Studies Are Performed Why Are BE Studies Performed? Deciding When Formulations Are Bioequivalent Potential Issues with TOST Bioequivalent Current International Regulation Some Practical Notes Testing for Average Bioequivalence Background Linear Model for 2 x 2 Data Applying the TOST Procedure Carry-over, Sequence, and Interaction Effects Checking Assumptions Made about the Linear Model Power and Sample Size for ABE in the 2 x 2 Design Example Where Test and Reference Are Not ABE Nonparametric Analysis BE Studies with More Than Two Periods Background Three-period Designs Within-subject Variability Robust Analyses for Three Period Designs Four-period Designs Designes with More Than Two Treatments Adjusting for Multiple Testing Nonparametric Analyses of Tmax Technical appendix: Efficiency Tables of Data Special Topics in Bioequivalence Dealing with Special BE Challenges Restricted Maximum Likelihood Modelling Failing BE and the DER Assessment Simulation Data-based Simulation Carry-over Optimal Designs Determining Trial Size What Outliers Are and How to Handle Their Data Bayesian BE Assessment Adaptive Bioequivalence Trials Background Two-stage design for testing for ABE TOST using the standard combination test Example of using the standard combination test The maximum combination test Example of using the maximum combination test Conditional errors and conditional power Algorithm for sample size re-estimation Operating characteristics Conclusions Techniccal Appendix: R code Scaled Average Bioequivalence Testing Background Scaled Average Bioequivalence in Europe Scaled Average Bioequivalence in USA Discussion and Cautions Clinical Pharmacology Clinical Pharmacology Safety Studies Background First-time-in-humans Sub-chronic Dosing Studies Food-Effect Assessment and DDIs Dose-Proportionality Technical Appendix QTc Background Modelling of QTc Data Interpreting the QTc Modelling Findings Design of a Thorough QTc Study in the Future Clinical Pharmacology Efficacy Studies Background Sub-chronic Dosing Phase IIa and the Proof of Concept Population Pharmacokinetics Population and Pharmacokinetics Absolute and Relative Bioavailability Age and Gender Pharmacokinetic Studies Ethnicity Liver Disease Kidney Disease Technical Appendix Vaccines & Epilogue Vaccine Trials Brief Introduction to Vaccine Research and Development Phase I Vaccine Studies Proof of Concept and Phase II Lot Consistency Concomitant Vaccination Cross-over Trials in Vaccines Epilogue Bibliography Index.
  • (source: Nielsen Book Data)9781466585218 20171218
Maintaining a practical perspective, Bioequivalence and Statistics in Clinical Pharmacology, Second Edition explores statistics used in day-to-day clinical pharmacology work. The book is a starting point for those involved in such research and covers the methods needed to design, analyze, and interpret bioequivalence trials; explores when, how, and why these studies are performed as part of drug development; and demonstrates the methods using real world examples. Drawing on knowledge gained directly from working in the pharmaceutical industry, the authors set the stage by describing the general role of statistics. Once the foundation of clinical pharmacology drug development, regulatory applications, and the design and analysis of bioequivalence trials are established, ã including recent regulatory changes in design and analysis and in particular sample-size adaptation, they move on to related topics in clinical pharmacology involving the use of cross-over designs. These include, but are not limited to, safety studies in Phase I, dose-response trials, drug interaction trials, food-effect and combination trials, QTc and other pharmacodynamic equivalence trials, proof-of-concept trials, dose-proportionality trials, and vaccines trials.ã This second edition addresses several recent developments in the field, including new chapters on adaptive bioequivalence studies, scaled average bioequivalence testing, and vaccine trials. Purposefully designed to be instantly applicable, Bioequivalence and Statistics in Clinical Pharmacology, Second Edition provides examples of SAS and R code so that the analyses described can be immediately implemented. The authors have made extensive use of the proc mixed procedures available in SAS.
(source: Nielsen Book Data)9781466585218 20171218
Book
1 online resource : text file, PDF.
  • Analytical characterization. Immunogenicity. Animal studies. Clinical development. Manufacturing, process control. Extrapolation of indications. Interchangeability, substitution. Pharmacovigilance. Statistical issues. Regulatory issues.
  • (source: Nielsen Book Data)9781498718806 20171218
When a biological drug patent expires, alternative biosimilar products are developed. The development of biosimilar products is complicated and involves numerous considerations and steps. The assessment of biosimilarity and interchangeability is also complicated and difficult. Biosimilar Drug Product Development presents current issues for the development of biosimilars and gives detailed reviews of its various stages and contributing factors as well as relevant regulatory pathways and pre- and post-approval issues.
(source: Nielsen Book Data)9781498718806 20171218
Book
xxiv, 241 pages : illustrations ; [ca. 23-29] cm.
  • Preface to the Second Edition. Introduction. Organization of a Safety Monitoring Program for a Confirmatory Trial. Meetings. Clinical Issues. Statistical Issues. Biases and Pitfalls. DMC Decisions. Emerging issues. Appendix.
  • (source: Nielsen Book Data)9781498784122 20171218
Praise for the first edition: "Given the author's years of experience as a statistician and as a founder of the first DMC in pharmaceutical industry trials, I highly recommend this book-not only for experts because of its cogent and organized presentation, but more importantly for young investigators who are seeking information about the logistical and philosophical aspects of a DMC." -S. T. Ounpraseuth, The American Statistician ã In the first edition of this well-regarded book, the author provided a groundbreaking and definitive guide to best practices in pharmaceutical industry data monitoring committees (DMCs). Maintaining all the material from the first edition and adding substantial new material, Data and Safety Monitoring Committees in Clinical Trials, Second Edition is ideal for training professionals to serve on their first DMC as well as for experienced clinical and biostatistical DMC members, sponsor and regulatory agency staff. The second edition guides the reader through newly emerging DMC responsibilities brought about by regulations emphasizing risk vs benefit and the emergence of risk-based monitoring. It also provides the reader with many new statistical methods, clinical trial designs and clinical terminology that have emerged since the first edition. The references have been updated and the very popular end-of-chapter Q&A section has been supplemented with many new experiences since the first edition. ã New to the Second Edition: Presents statistical methods, tables, listings and graphs appropriate for safety review, efficacy analysis and risk vs benefit analysis, SPERT and PRISMA initiatives. Newly added interim analysis for efficacy and futility section. DMC responsibilities in SUSARs (Serious Unexpected Serious Adverse Reactions), basket trials, umbrella trials, dynamic treatment strategies /SMART trials, pragmatic trials, biosimilar trials, companion diagnostics, etc. DMC responsibilities for data quality and fraud detection (Fraud Recovery Plan) Use of patient reported outcomes of safety Use of meta analysis and data outside the trial New ideas for training and compensation of DMC members ã Jay Herson is Senior Associate, Biostatistics, Johns Hopkins Bloomberg School of Public Health where he teaches courses on clinical trials and drug development based on his many years experience in clinical trials in academia and the pharmaceutical industry. ã ã ã ã ã ã ã ã ã ã ã ã ã .
(source: Nielsen Book Data)9781498784122 20171218
Video
1 streaming video file (84 min.) : digital, sound, color
The story of Dr. William Hurwitz--a preeminent pain specialist sentenced to 25 years in prison for drug trafficking--provides a window into the ethical dilemma of opioid prescriptions. Painkillers give doctors tremendous power to relieve pain, a primary goal of any physician. But this power begets trouble when the same drugs can lead to addiction, abuse and death. In 2004 Dr. William Hurwitz was convicted of over 50 counts of narcotics distribution and handed a 25-year prison sentence. Dr. Feelgood traces Dr. Hurwitz's trial and eventual appeal, detailing the events that led to his arrest. Testimonies from the witnesses in Dr. Hurwitz's case contradict one another--some revere him, while others condemn him. Taken together, their accounts reveal a profile of a compassionate yet flawed doctor. The film, in telling his story, underscores the tension between every patient's right to pain relief and the lawful need for drug control. There could not be a more critical time to spark discussion on the topic, and call for careful thought and action.
Book
318 pages : illustrations ; 22 cm
Green Library
Book
pages ; cm.
  • The Rationale and Economics of Drug Repositioning Repositioning approaches and technologies: from serendipity to systematic and rational strategies Successful cases of repositioned neurotherapeutics Current opportunities for drug repositioning in neuronal diseases Regulatory and Legal Issues.
  • (source: Nielsen Book Data)9781482220834 20171218
Nervous system diseases represent a major health concern worldwide. Although important financial and professional investment, their etiology and pathophysiology still remain mostly elusive. Moreover, the clinical need of disease-modifying therapies is still unmet. In the last decades, traditional R&D has failed in identifying new effective therapies in many medical areas and drug repositioning has recently emerged as a promising alternative strategy to de novo drug discovery to improve and accelerate therapeutic development. For the first time, Drug Repositioning: Approaches and Applications for Neurotherapeutics reviews history and advances in drug repositioning, with a special focus on therapeutics for nervous system diseases. International experts from Academia, Industry and Non-profit organisations will provide different views on drug repositioning advantages, challenges and specific applications, which will be covered for nervous system diseases including Alzheimer's, Parkinson's, Huntington's diseases, Amyotrophic Lateral Sclerosis, Spinal Muscular Atrophy, ischemic stroke, and psychiatric disorders. This book provides a balanced overview and synthesis of drug repositioning concept, methods and applications for neurotherapeutics. It represents a valuable resource for students, scientists and clinicians working in academic settings, industry and government agencies within the fields of neuroscience, pharmacology, neurology, pharmaceutical sciences, drug discovery and development.
(source: Nielsen Book Data)9781482220834 20171218
Book
xi, 197 pages : illustrations (some color) ; 26 cm
  • Malaria and Antimalarials The Painkiller, Aspirin Ether, Chloroform, Cocaine, Morphine, Heroin, and Anesthesia The Pill Diabetes and Insulin Smallpox and Vaccination Vaccines to Combat Infectious Diseases The Great Pox Syphilis and Salvarsan Prontosil, Pyrimethamine, and Penicillin AIDS, HIV, and Antiretrovirals Organ Transplantation and Cyclosporine Malaria, Madness and Chlorpromazine.
  • (source: Nielsen Book Data)9781498796491 20171218
Drugs are used in the diagnosis, alleviation, treatment, prevention or cure of disease. This is a book about drugs, how they came to be, and how they exert their `magic'. Today we have drugs to protect against infectious diseases, to alleviate aches and pains, to allow new organs to replace the old, and for brain functions to be modified. Yet, for the most part the manner by which drugs are developed and by whom remains a mystery. Drugs are more than just a pill or liquid and some have markedly altered history. The author has selected a few drugs - highlights representing milestones affecting our well-being and influencers of social change. The stories told are dramatic and include spectacular successes and dismal failures. And the people about whom these stories are told are both saints and sinners - selfless and conniving - bold and mercurial and shy and retiring loner. The drugs themselves mirror the diversity of their origin stories and the author assembles all sides of these fascinating stories.
(source: Nielsen Book Data)9781498796491 20171218
Book
1 PDF (xii, 195 pages).
  • PrefaceInflammation and the Endocannabinoid SystemCannabinoids in Multiple SclerosisHuntington's Disease and the Endocannabinoid SystemAlzheimer's, Neuroinflammation and the Endocannabinoid SystemThe Endocannabinoid System's Role in Ocular InflammationCannabidiol as a Potential Clinical Therapeutic Agent for the Reduction of Pancreatic Inflammation in Early Type 1 Diabetes MellitusRole of the Endocannabinoid System in Interstitial CystitisArthritis and the Endocannabinoid SystemCannabinoid 2 Receptor Activation in SepsisImmune Modulation by Cannabinoids During Central Nervous System Injury-induced NeuroinflammationLead Author BiographiesContributing Author BiographiesReferences.
  • (source: Nielsen Book Data)9781615047482 20171017
This book focuses on the role of the endocannabinoid system in local and systemic inflammation, with individual chapters written by experts in the field of cannabinoid research and medicine. The topics explore the actions of the endocannabinoid system on the immune system, including neuroinflammation in autoimmune disorders such as multiple sclerosis, and in neurodegenerative disorders such as Huntington's and Alzheimer's, as well as local and systemic inflammatory conditions affecting organs including the eye (uveitis and corneal inflammation), the bladder (interstitial cystitis), pancreas (diabetes), cardiovascular system (stroke), joints (arthritis), and sepsis. The objective of this book is to provide knowledge transfer on the use of cannabinoids in inflammatory disease by critically examining preclinical and clinical research on the immunomodulatory actions of the endocannabinoid system, with specific emphasis on the actions of cannabinoids in diseases where inflammation is a prominent component. By drawing these results together, we seek to provide further understanding of the complexities of endocannabinoid system modulation of immune function and identify potential uses and limitations for cannabinoid-based therapeutics.
(source: Nielsen Book Data)9781615047482 20171017

16. Fat chance [2007]

Video
1 streaming video file (52 min.) : digital, sound, color
When single mom and filmmaker Yuka Sekiguchi, overweight at nearly 200 pounds and fast approaching fifty, determines to lose weight in hopes of becoming healthier and happier, she decides to film her struggle, figuring that public humiliation will be a strong incentive to succeed. FAT CHANCE, by turns serious and humorous, chronicles her six-month effort, involving experiments with fad diets, machines that claim to break down body fat, exercise programs, diet shakes, and consultations with an obesity expert, a psychiatrist, and a plastic surgeon.
Book
xlviii, 810 pages : illustrations ; [ca. 23-29] cm
  • Chapter 1: Modes Of Reagent Addition - Control of Impurity Formation Chapter 2: Process Optimization Chapter 3: Hazardous Reactions Chapter 4: Catalytic Reactions Chapter 5: Grignard Reagent And Related Reactions Chapter 6: Challenging Reaction Intermediates Chapter 7: Protecting Groups Chapter 8: Reaction Solvents Chapter 9: Base Reagent Selection Chapter 10: Reagents For Amide Formation Chapter 11: Various Reagent Surrogates Chapter 12: Telescope Approach Chapter 13: Stereochemistry Chapter 14: Design Of New Synthetic Route Chapter 15: Reaction Workup Chapter 16: Pharmaceutical Salts Chapter 17: Solid Form.
  • (source: Nielsen Book Data)9781498767996 20171218
The Handbook for Chemical Process Research and Development focuses on developing processes for chemical and pharmaceutical industries. Forty years ago there were few process research and development activities in the pharmaceutical industry, partially due to the simplicity of the drug molecules. However, with the increasing structural complexity, especially the introduction of chiral centers into the drug molecules and strict regulations set by the EMA and FDA, process R&D has become one of the critical departments for pharmaceutical companies. This book assists with the key responsibility of process chemists to develop chemical processes for manufacturing pharmaceutical intermediates and final drug substances for clinical studies and commercial production.
(source: Nielsen Book Data)9781498767996 20171218
Book
1 online resource.
  • * The Cannabis Plant: Botanical Aspects * The biosynthesis of cannabinoids * Increasing plant concentrations of THC and implications on health related disorders * Age as a Predictor of Cannabis Use * Lifetime cannabis use and cognition in psychosis spectrum disorders * A Profile of Synthetic Cannabinoid Users * Dual disorders in cannabis misuse * Cannabis use and cognitive function * Cannabis, migration and psychosis onset * The global epidemiology and disease burden of cannabis use and dependence * International aspects of cannabis use and misuse - the Australian perspective * International aspects of cannabis use and misuse: Egypt * Cannabis Body Packing - A Caribbean Perspective * Gender differences in cannabis use disorders * The role of age in the onset and further development of cannabis use disorders * Effects of Cannabis Use on Neurocognition in Adolescents and Emerging Adults with Psychiatric Comorbidities * Correlates and consequences of prenatal cannabis exposure (PCE): identifying and characterizing vulnerable maternal populations and determining outcomes for exposed offspring * Cannabis and clubbing: Relevance of cannabis and polydrug use in the clubbing culture today * Cannabis and Sexual Behavior * Friendships and Cannabis Use * Students' knowledge of cannabis * Childhood trauma and cannabis - risk factors in severe mental disorders * Parent's Influence on Their Children's Cannabis Use * Cannabis Users and Premorbid Intellectual Quotient (IQ) * Cannabis and traffic accidents * Drug-related pictures, attentional bias, and cannabis use * Cannabis use and first-episode psychosis patients (FEP) * Cannabis, associative memory, fMRI, and the Implicit Association Test * Stress Response in Cannabis Users and Psychosis * Motivation in Chronic Cannabis Use * Cannabis use and its association to mental illness: a focus on mood and anxiety disorders * Cannabis Use and Well-being * Craving and cannabis: A potential paradox * Delta 9-tetrahydrocannabinol and catalepsy-like immobilization * The interactive nature of cannabis and schizophrenia risk genes * Neuroimaging findings in Adolescent Cannabis use and Early Phase Psychosis * Cannabis smoking in adult schizophrenia: A cognitive and functional magnetic resonance imaging perspective * The long-lasting effects of cannabis use on movement and brain regions that control movement * Assessment of cannabis acute effects on driving skills: laboratory, simulator and on road studies * Chronic cannabis use and axonal fibre connectivity * Microglial activation and cannabis exposure * Cannabis and psychosis: correlation, causality and consequences * Cannabis use and cannabis use disorders in bipolar disorder - causes and consequences * Cannabis use in epilepsy - risks and benefits * Cannabis, cannabinoids and visceral pain. * Cannabis and Post-Operative Analgesia * Chronic cannabis abuse and thyroid function * Cannabis Hyperemesis Syndrome * Cannabis and Cannabinoids and the effects on gastrointestinal function: an overview * Cardiovascular Effects of Cannabis Usage * Cannabis and Stroke * Cannabis Smoking and the Lung * Cannabis and hepatic injury * Cannabis allergy: more than a bad trip * Marijuana and Breastfeeding * Hypocretins/orexins and addiction: role in cannabinoid dependence * Regulatory role of cannabinoids for skin barrier functions and cutaneous inflammation * Cannabinoids and the Cannabinoid Receptors: An Overview * Signalling and Regulation of the Cannabinoid CB1 Receptor * Allosteric modulation of the Cannabinoid CB1 Receptor * The polymorphisms of the CB2 cannabinoid receptor * Chemistry of Cannabinoid Receptor Agonists * The endocannabinoid system as a target for new antiseizure drugs * Pharmacological aspects of anandamide and 2-arachidonoyglycerol as bioactive lipids * Pharmacological aspects of NMDA receptors, mGluR5, and endocannabinoids * Peripheral CB1 receptors and ghrelin in feeding regulation. Pharmacological implications. * Pharmacological aspects of novel antiobesity agents related to cannabinoids * Cannabinoid reward and dependence: Focus on the main psychoactive ingredients of marijuana in preclinical studies * Peroxisome proliferator activated receptors and cannabinoids VRP suggested Peroxisome proliferator activated receptors (PPARs) and cannabinoids * The Protein-Protein interactions of CRIP1a and cannabinoid 1 receptor: the molecular mechanism study through an integrated molecular modeling approach * Synthetic cannabinoids: A summary of selected phenomena with respect to behavioral pharmacology and abuse liability * The role of 5-HT1A receptor and nausea and vomiting relief by cannabidiol (CBD), cannabidiolic acid (CBDA) and cannabigerol (CBG) * Genetic and molecular aspects of addiction with tetrahydrocannabinol * Effects of dlta 9-Tetrahydrocannabinol in human breast cancer *DELTA9-THC and COX-2 Signaling * Cannabinoids and the addictive effects of nicotine * Cannabinoid Regulation of Intraocular Pressure: Human and Animal Studies, Cellular and Molecular Targets * Ocular Delivery of Tetrahydrocannabinol * The role of g-aminobutyric acid in the interoceptive effects of oral D9-tetrahydrocannabinol in humans * The role of the delta-9-tetrahydrocannabinol in diabetes mellitus * Cannabidiol: An Overview of its Antipsychotic Properties * Cannabidiol for the treatment of epilepsy: an overview of possible mechanisms of action and preclinical and human studies * Cannabidiol and neuroprotection: evidence from preclinical studies * Cannabinoids as Potent Inhibitors of Human CYP1 Enzymes * Nabilone: Pharmacology and Clinical Applications (Suggest: The Synthetic Analogue of delta 9-tetrahydrocannabinol (THC): Nabilone. Pharmacology and Clinical Application) * Synthetic cannabinoids in dementia * Synthetic cannabinoid receptor agonists ("Spice") as new recreational psychoactive substances * Accidents and synthetic cannabinoids in blood of drivers * Cannabis and synthetic cannabinoids for cancer patients: Multiple palliative indications together with promising laboratory anti-neoplastic effects * The Use of Medical Marijuana in the Treatment of Psychiatric Disorders * Beneficial effects of cannabis and related compounds on sleep * Cannabinoids for the treatment of Gilles de la Tourette syndrome * Cannabidiol and multiple sclerosis * Cannabinoids and Effects on Painful Neuropathy * Cannabis for basal ganglia disorders (Parkinson's disease and Huntington's disease) * Medical cannabis for the treatment of Inflammatory Bowel Disease * Cannabidiol for the treatment of drug use disorders * Cannabinoids and the effects on gastrointestinal tract: a focus on motility * Potential medical uses of cannabigerol: a brief overview * The Cannabis Abuse Screening Test (CAST) and applications * Screening of synthetic cannabinoids * On-site Drug testing for Cannabis * Cannabinoids in Oral Fluid: Identification and Interpretation of Analytical Results * Cannabinoids in exhaled breath * Barriers to treatment seeking for cannabis dependence * Pharmacotherapies for cannabis use disorders * Self-Initiated Cannabis Use Cessation in Adolescents and Emerging Adults * Treating cannabis dependent adolescents with family therapy * Cognitive Behavioral Therapy in Cannabis Use Disorder * Cannabis withdrawal symptoms in cannabis and poly drug users * School-based cannabis prevention programs * The CapOpus trial for cannabis use disorders * Treating cannabis use disorders through technology assisted interventions: the telephone and internet * Reducing cannabis use with a real-time intervention using mobile technology * Further information: Cannabis Neuropathology Resources and Recommended Reading Online Only Chapters: * Tetrahydrocannabinol concentration and genetic characterization of cannabis.* Cannabis Use in Youth Subcultures* Aggressive Behavior and Cannabis Use* COMT genotypes, cannabis use and psychosis: gene-environment interaction evidence from human populations and its methodological concerns* Neuroimaging and genetics of acute and chronic cannabis effects* Grey matter, lateral ventricle volumes and executive functioning in cannabis users with first-episode psychosis* Comorbidity Between Cannabis Use and Attention-Deficit/Hyperactivity Disorder: Potential Moderators * Cannabis and Oral Bones: Deleterious Effects on Periodontitis and Dental Implants* Does cannabis use increase the risk of developing cancer in humans? * Cannabis and the use of amphetamine-like substances* Cannabinoid signaling in glioma cells and therapeutic implications* Cannabidiol as antioxidants* The anxiolytic effects of cannabidiol (CBD).* New Ethological and Morphological Perspectives for the Investigation of Panicolytic-Like Effects of Cannabidiol* Spice Use amongst United States Military Personnel* Cannabis use in fibromyalgia* Short instruments to screen for "problematic" cannabis use in general population surveys: a systematic review* Self-report of cannabis use* CANDIS Program: Modular Treatment of Cannabis Use Disorders* Engaging Cannabis Users in Treatment.
  • (source: Nielsen Book Data)9780128007563 20170313
Handbook of Cannabis and Related Pathologies: Biology, Pharmacology, Diagnosis, and Treatment is the first book to take an interdisciplinary approach to the understanding of cannabis use and misuse. Recent worldwide trends toward decriminalizing marijuana for medical use have increased legal use of the drug and recreational use remains high, making cannabis one of the most commonly used drugs. Cannabis has a wide range of adverse neurological effects, and use and abuse can lead to physical, social, and psychopathological issues that are multifarious and complex. Effective understanding and treatment requires knowledge of the drug's effects from across scientific disciplines. This book provides an overview of the biological and pharmacological components of the cannabis plant, outlines its neurological, social, and psychopathological effects, assists in the diagnosis and screening for use and dependency, and aids researchers in developing effective treatments for cannabis-related issues and disorders. Fully illustrated, with contributions from internationally recognized experts, it is the go-to resource for neuroscientists, pharmacologists, pathologists, public-health workers, and any other researcher who needs an in-depth and cross-disciplinary understanding of cannabis and its effects.
(source: Nielsen Book Data)9780128007563 20170313
Book
1 online resource (1170 pages) : illustrations (some color)
  • What is Low-Level Laser (Light) Therapy? Marcelo Victor Pires de Sousa History of Low-Level Laser (Light) Therapy Michael R. Hamblin Lasers, LEDs, and Other Light Sources James Carroll Is Coherence Important in Photobiomodulation? Tomas Hode Tissue Optics Bryan James Stephens and Linda Ramball Jones Light-Tissue Interaction and Light Dosimetry Ana Carolina de Magalhaes and Elisabeth Mateus Yoshimura Mitochondrial Light Absorption and Its Effect on ATP Production Nicolette Houreld Water as a Photoacceptor, Energy Transducer, and Rechargeable Electrolytic Bio-battery in Photobiomodulation Luis Santana-Blank, Elizabeth Rodr'iguez-Santana, Jes 'us A. Santana-Rodr'iguez, Karin E. Santana-Rodriguez, and Heberto Reyes-Barrios Role of Reactive Oxygen Species in Low-Level Laser Therapy Vikrant Rai Molecular Basis for Photobiomodulation: Light-Induced Nitric Oxide Synthesis by Cytochrome c Oxidase in Low-Level Laser Therapy Robert Oliver Poyton and Marina Hendrickson Cytoprotective Effect of Low-Level Light Therapy using LEDs on Neurons Margaret Wong-Riley and Huan Ling Liang Low-Level Laser and Cultured Neural Tissue Patricia J. Armati and Roberta T. Chow Shining a Light on Parkinson's Disease Daniel McKenzie Johnstone, Cecile Moro, Jonathan Stone, Alim-Louis Benabid, and John Mitrofanis Low-Level Laser Therapy and Stem Cells Qi Zhang, Chang Zhou, and Tingting Dong Antimicrobial Photodynamic Therapy Vanderlei Salvador Bagnato, Cristina Kurachi, Kate Cristina Blanco, and Natalia Mayumi Inada Low-Level Laser (Light) Therapy forWound Healing in Animal Models Andre Luiz Oliveira Ramos, Felipe Scholz Ramos, and Marcelo Victor Pires de Sousa Low-Level Laser Therapy for Arthritis in Animal Models: Beneficial Effect and Action Mechanism Flavio Aimbire and Paulo de Tarso Camilo de Carvalho Low-Level Laser Therapy for Lung Diseases: From the Bench to the Bed Flavio Aimbire Low-Level Laser (Light) Therapy in Tendon Healing in in Vitro and in Vivo Models Lucas F. de Freitas and Michael R. Hamblin Bone Repair in Animal Models Antonio Luiz B. Pinheiro, Luiz G. Pinheiro Soares, and Aparecida Maria C. Marques Transcranial Low-Level Laser (Light) Therapy for Stroke and Traumatic Brain Injury in Animal Models Michael R. Hamblin, Luis De Taboada, and Ying-Ying Huang Phototherapy in Peripheral Nerve Repair and Muscle Preservation Shimon Rochkind Low-Level Laser Therapy for Spinal Cord Repair Takahiro Ando and Michael R. Hamblin Low-Level Laser (Light) Therapy for the Treatment of Visual System Injury and Disease Janis T. Eells, Sandeep Gopalakrishnan, Michele M. Salzman, Krisztina Valter, Jan Provis, Ricardo Natoli, John Mitrofanis, Jonathan Stone, and Melinda Fitzgerald Protection from Cardiac Ischemia and Reperfusion Injury Agnes Keszler, Svjetlana Dosenovic, and Martin Bienengraeber Low-Level Laser and Experimental Aortic Aneurysm: Mechanisms and Therapeutic Implications Lilach Gavish and S. David Gertz Low-Level Laser Therapy: A Treatment Modality for Multiple Sclerosis Targeting Autoimmunity and Oxidative Stress Zenas George, Miguel A. Tolentino, and Jeri-Anne Lyons Low-Level Laser Therapy as an Alternative Treatment for Snake Envenomation Camila Squarzoni Dale and Stella Regina Zamuner Veterinary Low-Level Laser (Light) Therapy Applications for Companion Animals Richard L. Godine Emergence of Low-Level Laser (Light) Therapy in Clinical Veterinary Practice Ronald E. Hirschberg Photomedicine for Exotic Animals: A Case-Based Discussion Narda G. Robinson Recalcitrant Wound: Using Low-Level Laser (Light) Therapy to Manage Non-Healing Wounds and Ulcers Raymond J. Lanzafame and Istvan Stadler Clinical Applications with Low-Level Laser Therapy in Arthritis Jan M. Bjordal Use of Low-Level Laser Therapy and Light-Emitting Diode Therapy to Improve Muscle Performance and Prevent Damage: From Animal Models to Clinical Trials Cleber Ferraresi, Nivaldo Parizotto, Vanderlei Bagnato, and Michael R. Hamblin Low-Level Laser Therapy of Pain: Clinical Applications Roberta T. Chow Low-Level Laser Therapy and Its Application in Tinnitus Alessandra Nara de Souza Rastelli, Emanuelle Teixeira Carrera, Gustavo Nicolodelli, and Michael R. Hamblin Laser Therapy for the Treatment of Radiculopathy Jerome M. True and Luis C. Vera Difficult Path to Treating Acute Ischemic Stroke Patients with Transcranial Near-Infrared Laser Therapy Paul A. Lapchak, Pramod Butte, and Padmesh S. Rajput Low-Level Laser (Light) Therapy for Rehabilitation in Traumatic Brain Injury and Stroke, including Chronic Aphasia Margaret A. Naeser, Paula I. Martin, Michael D. Ho, Maxine H. Krengel, Yelena Bogdanova, Jeffrey A. Knight, Megan K. Yee, Ross Zafonte, Bang-Bon Koo, John G. Roubil, and Michael R. Hamblin Transcranial Near-Infrared Light for Major Depressive Disorder: Targeting the Brain Metabolism Paolo Cassano, Abigail R. Archibald, and Dan V. Iosifescu Low-Level Laser Therapy: A Corner Stone in the Management of Cancer Therapy-Induced Mucositis Rene-Jean Bensadoun, Idriss Troussier, and Raj G. Nair Photobiomodulation in Dentistry: Manipulating Biostimulation and Bioinhibition for Clinical Success Gerry Ross and Alana Ross Photobiomodulation for the Clinical Treatment of Age-Related Macular Degeneration Graham Merry and Robert Dotson Laser (Light) Therapy for Postherpetic Neuralgia Kevin C. Moore and R. Glen Calderhead Laser Acupuncture Lucas F. de Freitas and Michael R. Hamblin Intravascular Laser Irradiation of Blood Daiane Thais Meneguzzo, Leila Soares Ferreira, Eduardo Machado de Carvalho, and Cassia Fukuda Nakashima Nonsurgical Laser Therapy for Type 1 and Type 2 Diabetes Leonardo Longo Laser Therapy of Traumatic Central Nervous System Injuries Leonardo Longo and Diego Longo Low-Level Laser (Light) Therapy: Aesthetic Applications for Hair Felipe Scholz Ramos, Andr'e Luiz de Oliveira Ramos, and Marcelo Victor Pires de Sousa Low-Level Laser (Light) Therapy for Cosmetics and Dermatology Mossum K. Sawhney and Michael R. Hamblin Low-Level Laser Therapy for Body Contouring and Fat Reduction Gaurav K. Gupta Transcranial Low-Level Laser (Light) Therapy for Neurocognitive Enhancement Julio C. Rojas and F. Gonzalez-Lima Post-Operative Uses of Low-Level Laser Therapy Maria Cristina Chavantes, Nathali Cordeiro Pinto, and Vanessa Milanesi Holanda Bright New World: Future Directions of Low-Level Laser (Light) Therapy Marcelo Victor Pires de Sousa and Maria Cristina Chavantes.
  • (source: Nielsen Book Data)9789814669603 20171218
Low-Level Laser Therapy (LLLT) also known as photobiomodulation is almost 50 years old, and recently has been getting increasing acceptance from the scientific, medical, and veterinary communities. Discoveries are constantly being made about the cellular and molecular mechanisms of action, the range of diseases that can be treated is also rising, and home use LED devices are becoming common. This book compiles cutting-edge contributions from the world's leading experts in Photobiomodulation and LLLT. Chapters cover general concepts, mechanisms of action, in vitro studies, pre-clinical animal studies, veterinary applications and a wide range of clinical topics. Edited by Michael Hamblin from Massachusetts General Hospital and Harvard Medical School, aided by two prominent researchers (Marcelo Sousa and Tanupriya Agrawal), this book will appeal to anyone involved in the basic science, translational aspects and clinical applications of LLLT.
(source: Nielsen Book Data)9789814669603 20171218
Book
xiv, 1353 pages ; 29 cm
Medical Library (Lane)